Using GNMT as a Novel Therapeutic or Preventing Agent for Fatty Liver Related Diseases
AssigneeNational Yang-Ming University
InventorsYi-Ming CHEN, Chia-Hung YEN, Yi-Jen LIAO, Kuan-Hsuan CHEN
Life of this patent
Estimating the term…
Abstract
The present invention relates to a use of Glycine N-methyltransferase (GNMT) in treating or preventing fatty liver related disease, such as nonalcoholic fatty liver disease (NAFLD) or hepatocellular carcinoma (HCC). The use of GNMT for treating or preventing fatty liver diseases is achieved by enhancing GNMT-NPC2 interaction, and thus decreasing or preventing the accumulation of lipid and cholesterol in hepatic cells or tissues.
Claims9
A pharmaceutical composition for in treating or preventing fatty liver related disease, comprising Glycine N-methyltransferase (GNMT) as active ingredient, and a pharmaceutically acceptable carrier, diluent or excipient.
A method for diagnosing the occurrence of fatty liver disease in a tested animal, comprising collecting a blood or liver sample from the animal;
- and detecting the content or expression level of GNMT protein by using a detecting agent.
Dependencies are inferred from the claim text.